Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease March 30, 2026 View Press Release
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results February 26, 2026 View Press Release
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) January 8, 2026 View Press Release
Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease December 22, 2025 View Press Release
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) December 5, 2025 View Press Release
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) November 7, 2025 View Press Release
Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress November 5, 2025 View Press Release
Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease November 3, 2025 View Press Release
Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock October 21, 2025 View Press Release